The Lipidome Score: How Replacing Saturated Fat Cuts CV and T2D Risk

This 2024 multi-cohort analysis, published in Nature Medicine, constructed a 45-metabolite multilipid score (MLS) that captures the biological fingerprint of replacing saturated fat with unsaturated fat -- including olive oil-rich Mediterranean patterns -- and tested whether that lipidome signature predicted future cardiovascular disease and type 2 diabetes. According to PubMed (DOI), participants with a more favorable MLS had 32% lower incident cardiovascular disease and 26% lower incident type 2 diabetes in the EPIC-Potsdam cohort.

Why This Study Matters

Cardiometabolic guidelines have advised replacing saturated fat with unsaturated fat for decades. That guidance rests on consistent epidemiological and trial evidence, but the underlying biology -- exactly which lipid changes mediate the cardiometabolic benefit -- has been opaque. Dietary fat composition shifts the concentrations of hundreds of distinct lipid species in blood, and which of those shifts actually carry the protective signal has been an open question.

This analysis took a different methodological route. The investigators used lipidomics -- mass-spectrometry quantification of individual lipid species -- to construct a score that summarizes the lipid changes induced by replacing saturated with unsaturated fat in a controlled feeding trial. They then tested whether that score, measured at baseline in independent cohorts, predicted future cardiovascular and metabolic disease.

The result is a precision-nutrition tool. Rather than asking "did you eat saturated fat?", the score asks "does your blood look like a person who replaced saturated with unsaturated fat?" The biological readout sidesteps recall bias and captures the cumulative metabolic effect of dietary fat quality.

How It Was Designed

The investigators built the multilipid score from a randomized controlled feeding trial in which participants substituted unsaturated for saturated fat. Lipidomic profiling on serum samples identified 45 lipid metabolites whose concentrations shifted significantly in response to the substitution. The weighted sum of those 45 metabolites became the MLS -- a single number summarizing the lipid signature of better dietary fat quality.

The MLS was then applied to three independent populations. EPIC-Potsdam, a large German cohort, provided the primary prospective validation: participants with higher MLS at baseline were followed for incident cardiovascular disease and type 2 diabetes. The Nurses' Health Study, in which the investigators tracked MLS changes over 10 years, allowed them to test whether improvement in the score over time predicted lower diabetes risk. The PREDIMED trial provided a different test: whether a Mediterranean diet intervention with olive oil shifted the score most among participants whose pre-intervention lipidome was furthest from the favorable signature.

A simplified score called the reduced MLS (rMLS) was also derived and shown to closely correlate with the full 45-metabolite version, supporting its use in settings where lipidomic profiling is constrained.

What They Found

Across the three cohort tests, the multilipid score predicted cardiometabolic outcomes consistently:

Cohort and Outcome	Effect Estimate (95% CI)	Risk Reduction	What It Measures
EPIC-Potsdam: CVD incidence	-32% (21-42%)	32% lower	New CVD events per favorable MLS shift
EPIC-Potsdam: T2D incidence	-26% (15-35%)	26% lower	New T2D cases per favorable MLS shift
Nurses' Health: T2D per SD rMLS improvement	OR 0.76 (0.59-0.98)	24% lower odds	T2D risk per 1-SD score improvement
PREDIMED: MedDiet effect on T2D	Greatest in low pre-intervention rMLS	Subset effect	Where intervention helped most

Green indicates a favorable direction. A higher multilipid score reflects better dietary fat quality and was associated with significantly lower cardiovascular and metabolic disease risk across all three cohorts.

Reading the Results

The findings group around three interconnected observations worth understanding together.

The biology of dietary fat replacement is now measurable in blood. The 45-metabolite multilipid score captures, with mass-spectrometry precision, the lipid changes induced when a person replaces saturated fat with unsaturated fat. That biological readout sidesteps the methodological weakness of food frequency questionnaires (recall bias, misreporting) and the difficulty of randomizing decades-long dietary patterns. The MLS is essentially a blood-level diagnostic for cardiometabolic dietary quality.

The same score predicts both cardiovascular disease and type 2 diabetes. The 32% lower CVD risk and 26% lower T2D risk in EPIC-Potsdam suggest the underlying biology connects both outcomes through shared lipid-mediated mechanisms. This is consistent with the broader cardiometabolic syndrome literature in which atherogenic dyslipidemia and insulin resistance share pathophysiological roots in dietary fat composition.

The Mediterranean diet's diabetes benefit is concentrated in participants with poor baseline lipid signatures. In PREDIMED, the EVOO-supplemented Mediterranean intervention reduced diabetes incidence primarily among participants whose pre-intervention rMLS was unfavorable -- the people whose lipidome reflected diets high in saturated fat. Those with already-favorable rMLS gained less from the intervention because their lipid biology was already in the protective range. This is a precision-nutrition finding: the same diet helps some people more than others, and the lipidome can identify who will benefit most.

What Didn't Change

This is a multi-cohort analytical study, not a single interventional trial. The EPIC-Potsdam and Nurses' Health observations are prospective but observational. The PREDIMED subset analysis is post-hoc within a randomized trial. Causal inference about the multilipid score itself is limited by the observational components, even though the underlying dietary fat replacement framework rests on randomized feeding trial data.

The score also requires lipidomic profiling, which is currently a research tool more than a clinical one. The reduced multilipid score (rMLS) addresses this partially by using fewer metabolites, but routine clinical implementation is not yet feasible.

Broader Context

This analysis sits at the intersection of three established research streams. The PREDIMED trial (2013, republished 2018 in NEJM) demonstrated 30% lower major cardiovascular events with a Mediterranean diet supplemented with extra virgin olive oil. The Guasch-Ferre 2022 Harvard cohort showed 19% lower all-cause mortality with higher olive oil intake. The 2021 American Heart Association scientific statement (Circulation) explicitly recommends replacing tropical and partially hydrogenated fats with liquid plant oils like olive oil.

This 2024 lipidome analysis adds a mechanistic backbone to that body of evidence. It identifies the specific lipid species through which dietary fat quality translates into cardiometabolic outcomes, and provides a measurable biomarker for the cumulative effect of the dietary shift. The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg of hydroxytyrosol and derivatives per day. The MLS reflects monounsaturated fat replacement effects rather than polyphenol-specific effects, but the two operate complementarily within the Mediterranean dietary pattern.

Related Research

Continue exploring olive oil and polyphenol science:

• American Heart Association 2021 Dietary Guidance: Olive Oil's Role
• Olive Oil and 14% Lower CV Risk in 90,000+ US Adults
• Olive Oil Activated the GLP-1 Pathway in a Controlled Trial

Source: View the original study on PubMed

Olivea's Dosage

This analysis did not test a specific olive oil dose. Its contribution is in defining the lipid signature of healthy dietary fat replacement, which the Mediterranean pattern and olive oil intake reliably produce. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams of monounsaturated-fat-rich oil and aligns with the kind of fat-quality shift the multilipid score captures. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.